Nordic Pharma (via Amring) Acquires Visant Medical to Launch LACRIFILL in U.S.
December 18, 2023
Nordic Pharma Group B.V., through its U.S. subsidiary Amring Pharmaceuticals Inc., has completed the acquisition of Visant Medical, Inc., bringing the FDA-cleared hyaluronic acid canalicular occlusive device LACRIFILL into the Nordic Pharma portfolio. Nordic will launch and commercialize LACRIFILL in the United States, expanding its ophthalmology product offering and enabling future global regulatory filings.
- Buyers
- Nordic Pharma Group B.V., Amring Pharmaceuticals Inc.
- Targets
- Visant Medical, Inc.
- Industry
- Medical Devices
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Haemonetics Acquires Vivasure Medical
January 11, 2026
Medical Devices
Haemonetics Corporation has acquired Galway-based Vivasure Medical in a transaction valued at up to €185 million, consisting of an upfront €100 million payment plus up to €85 million in contingent milestone payments. The acquisition adds Vivasure's PerQseal Elite fully bioabsorbable vascular closure system to Haemonetics' large-bore closure portfolio; Vivasure has CE Mark approvals and has submitted a PMA to the U.S. FDA.
-
Recipharm AB Acquires Vibalogics from Ampersand Capital Partners
February 18, 2022
Biotechnology
Recipharm AB, a global CDMO based in Sweden, has agreed to acquire Vibalogics, a virotherapy-focused CDMO and Ampersand Capital Partners portfolio company. The deal expands Recipharm's capabilities into viral vaccines, viral vectors and oncolytic virus manufacturing while Vibalogics will continue operating from its Boxborough, MA and Cuxhaven, Germany facilities.
-
Alcon Acquires Ivantis, Inc.
January 10, 2022
Medical Devices
Alcon has completed its acquisition of Ivantis, Inc., the developer of the Hydrus Microstent, integrating Ivantis’ manufacturing and sales employees to expand Alcon’s global surgical ophthalmology portfolio. Alcon said it will leverage its global footprint to broaden Hydrus Microstent availability and continue clinical research, including pursuing stand‑alone surgery indications in the U.S.
-
Avesi Partners Invests in Visante
February 12, 2024
Healthcare Services
Avesi Partners has made a minority growth investment in Visante, a St. Paul–based provider of tech-enabled pharmacy consulting and services for health systems. The partnership will support Visante’s growth and capability expansion across specialty and infusion pharmacy markets and includes an internal leadership transition with Steve Rough named CEO and Jim Jorgenson moving to an advisory role.
-
Santen Acquires Eyevance Pharmaceuticals for $225M
September 16, 2020
Pharmaceuticals
Santen Pharmaceutical Co., Ltd., through its U.S. subsidiary Santen Holdings U.S. Inc., acquired all outstanding shares of Eyevance Pharmaceuticals Holdings Inc. for $225 million in cash. The deal brings Eyevance’s topical ophthalmic product portfolio and U.S. commercial team into Santen’s global ophthalmology business; two development-stage assets (VISOVANQ and NEXAGON) were carved out and excluded from the purchase.
-
Linden Capital Partners Acquires Alcresta Therapeutics
March 12, 2024
Medical Devices
Chicago-based private equity firm Linden Capital Partners has completed its acquisition of Alcresta Therapeutics from a group led by Athyrium Capital, with Bessemer Venture Partners, Frazier Healthcare Partners and HealthQuest Capital also selling (HealthQuest reinvested as a minority shareholder). Linden will work with Alcresta's management and a newly assembled board to support the commercial launch of the next-generation RELiZORB device and accelerate R&D and growth.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.